Acquisition Of Thyrocare To Ease Pharmeasy’s Digital Offerings: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Online pharmacy startup Pharmeasy announced acquisition of Thyrocare Technologies Ltd., with a view to add diagnostic services in its digital offerings through biochemistry/pathology business.
Pharmeasy’s parent company API Holdings signed a definitive agreement to acquire a 66.1% stake in Thyrocare for Rs 45.5 billion.
The Docon Technologies (partner in the acquisition), a 100% subsidiary of API, will make an open offer of Rs 1,300 per share for an additional 26% stake as per Securities and Exchange Board of India guidelines.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.